Format

Send to

Choose Destination
Int J Antimicrob Agents. 2000 Sep;16(1):61-3.

In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis.

Author information

1
Department of Pediatrics, State University of New York, SUNY Health Science Center at Brooklyn, 11203-2098, USA.

Abstract

We evaluated the in vitro activity of GAR-936, a novel glycylcycline antibiotic, against ten isolates of Chlamydia pneumoniae and five strains of C. trachomatis. Susceptibility testing was done in HEp-2 cells. The MIC90s and MBC90s of GAR-936, doxycycline, ofloxacin and clarithromycin against C. pneumoniae were 0.125, 0.25, 0.25 and 0.06 mg/l, respectively. The MICs and MBCs of GAR-936, doxycycline, ofloxacin and clarithromycin against C. trachomatis were 0.03-0.125, 0.25, 0.25-0.5 and 0.06 mg/l, respectively. GAR-936 had excellent activity against both chlamydial species and may have a potential role in the treatment of human chlamydial infection.

PMID:
11185415
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center